Orphan Medical Busulfanex
Executive Summary
FDA's Oncologic Drugs Advisory Committee will meet Jan. 13 to discuss NDA 20-954 for busulfan for use in combination with chemotherapy or radiotherapy as a conditioning regimen for patients receiving hematopoetic progenitor cell transplant. The meeting is scheduled to begin at 8:30 a.m. at the Gaithersburg Holiday Inn